A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Latest Information Update: 22 Mar 2024
At a glance
- Drugs Resmetirom (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Registrational
- Acronyms MAESTRO-NAFLD-1
- Sponsors Madrigal Pharmaceuticals
- 14 Mar 2024 According to Food and Drug Administration media release, the Food and Drug Administration (FDA) granted accelerated approval of a first of its kind drug therapy, resmetirom, for the treatment of nonalcoholic steatohepatitis (NASH) in patients who have progressed to fibrosis
- 14 Nov 2023 Results (n=34) determining whether these NEXT GENER-ATION (NGEN) HepQuant Tests, using Risk ACE as endpoint, could detect treatment effects in MAESTRO-NAFLD-1, an open label, single arm study of resmetirom, studied for the treatment of NASH presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases
- 06 Nov 2023 According to a Madrigal Pharmaceuticals media release, data from this study were published in Nature Medicine.